Opioid agonist treatment and risk of mortality during opioid overdose public health emergency: population based retrospective cohort study

被引:132
|
作者
Pearce, Lindsay A. [1 ]
Min, Jeong Eun [1 ]
Piske, Micah [1 ]
Zhou, Haoxuan [1 ]
Homayra, Fahmida [1 ]
Slaunwhite, Amanda [2 ]
Irvine, Mike [2 ]
McGowan, Gina [3 ]
Nosyk, Bohdan [1 ,4 ]
机构
[1] British Columbia Ctr Excellence HIV AIDS, Hlth Econ Res Unit, Vancouver, BC V6Z 1Y6, Canada
[2] British Columbia Ctr Dis Control & Prevent, Vancouver, BC V5Z 4R4, Canada
[3] British Columbia Minist Mental Hlth & Addict, Victoria, BC V8W 9P1, Canada
[4] Simon Fraser Univ, Fac Hlth Sci, Burnaby, BC V5A 1S6, Canada
来源
BMJ-BRITISH MEDICAL JOURNAL | 2020年 / 368卷
关键词
PHARMACOLOGICAL-TREATMENT; METHADONE; DRUG; BUPRENORPHINE; DEPENDENCE; HEROIN; THERAPY;
D O I
10.1136/bmj.m772
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective - To compare the risk of mortality among people with opioid use disorder on and off opioid agonist treatment (OAT) in a setting with a high prevalence of illicitly manufactured fentanyl and other potent synthetic opioids in the illicit drug supply. Design - Population based retrospective cohort study. Setting - Individual level linkage of five health administrative datasets capturing drug dispensations, hospital admissions, physician billing records, ambulatory care reports, and deaths in British Columbia, Canada. Participants - 55 347 people with opioid use disorder who received OAT between 1 January 1996 and 30 September 2018. Main outcome measures - All cause and cause specific crude mortality rates (per 1000 person years) to determine absolute risk of mortality and all cause age and sex standardised mortality ratios to determine relative risk of mortality compared with the general population. Mortality risk was calculated according to treatment status (on OAT, off OAT), time since starting and stopping treatment (1, 2, 3-4, 5-12, >12 weeks), and medication type (methadone, buprenorphine/naloxone). Adjusted risk ratios compared the relative risk of mortality on and off OAT over time as fentanyl became more prevalent in the illicit drug supply. Results- 7030 (12.7%) of 55 347 OAT recipients died during follow-up. The all cause standardised mortality ratio was substantially lower on OAT (4.6, 95% confidence interval 4.4 to 4.8) than off OAT (9.7, 9.5 to 10.0). In a period of increasing prevalence of fentanyl, the relative risk of mortality off OAT was 2.1 (95% confidence interval 1.8 to 2.4) times higher than on OAT before the introduction of fentanyl, increasing to 3.4 (2.8 to 4.3) at the end of the study period (65% increase in relative risk). Conclusions - Retention on OAT is associated with substantial reductions in the risk of mortality for people with opioid use disorder. The protective effect of OAT on mortality increased as fentanyl and other synthetic opioids became common in the illicit drug supply, whereas the risk of mortality remained high off OAT. As fentanyl becomes more widespread globally, these findings highlight the importance of interventions that improve retention on opioid agonist treatment and prevent recipients from stopping treatment.
引用
收藏
页数:13
相关论文
共 50 条
  • [31] Duration of medication treatment for opioid-use disorder and risk of overdose among Medicaid enrollees in 11 states: a retrospective cohort study
    Burns, Marguerite
    Tang, Lu
    Chang, Chung-Chou H.
    Kim, Joo Yeon
    Ahrens, Katherine
    Allen, Lindsay
    Cunningham, Peter
    Gordon, Adam J.
    Jarlenski, Marian P.
    Lanier, Paul
    Mauk, Rachel
    McDuffie, Mary Joan
    Mohamoud, Shamis
    Talbert, Jeffery
    Zivin, Kara
    Donohue, Julie
    ADDICTION, 2022, 117 (12) : 3079 - 3088
  • [32] A retrospective cohort study of mortality rates in patients with an opioid use disorder treated with implant naltrexone, oral methadone or sublingual buprenorphine
    Kelty, Erin
    Joyce, David
    Hulse, Gary
    AMERICAN JOURNAL OF DRUG AND ALCOHOL ABUSE, 2019, 45 (03): : 285 - 291
  • [33] Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies
    Sordo, Luis
    Barrio, Gregorio
    Bravo, Maria J.
    Iciar Indave, B.
    Degenhardt, Louisa
    Wiessing, Lucas
    Ferri, Marica
    Pastor-Barriuso, Roberto
    BMJ-BRITISH MEDICAL JOURNAL, 2017, 357 : j1550
  • [34] Association between prescribed stimulant medications and overdose among individuals receiving opioid agonist therapy: A retrospective cohort study from British Columbia, Canada
    Young, Samantha
    Fairbairn, Nadia
    Cui, Zishan
    Bach, Paxton
    Mok, Wing Yin
    Budau, Juls
    Slaunwhite, Amanda
    Ti, Lianping
    Hayashi, Kanna
    Nolan, Seonaid
    ADDICTION, 2025,
  • [35] Risk factors for 48-hours mortality after prehospital treatment of opioid overdose
    Wichmann, Sine
    Nielsen, Soren Loumann
    Siersma, Volkert Dirk
    Rasmussen, Lars S.
    EMERGENCY MEDICINE JOURNAL, 2013, 30 (03) : 223 - 225
  • [36] Effectiveness and Public Health Impact of Safer Supply and Opioid Agonist Treatment: A Narrative Review with Recommendations
    Kahan, Meldon
    CANADIAN JOURNAL OF ADDICTION, 2024, 15 (02) : 6 - 16
  • [37] Evaluating the association between urine drug screening frequency and retention in opioid agonist treatment in Ontario, Canada: a retrospective cohort study
    Morin, Kristen A.
    Dabous, John R.
    Vojtesek, Frank
    Marsh, David
    BMJ OPEN, 2022, 12 (10):
  • [38] Trajectories of Retention in Opioid Agonist Therapy and Overdose Risk During a Community-Wide Overdose Epidemic in a Canadian Setting
    Eugenia Socias, M.
    Dong, Huiru
    Wood, Evan
    Nolan, Seonaid
    Hayashi, Kanna
    Kerr, Thomas
    Milloy, M-J
    AMERICAN JOURNAL OF PREVENTIVE MEDICINE, 2021, 60 (01) : 57 - 63
  • [39] Association between benzodiazepine coprescription and mortality in people on opioid replacement therapy: a population-based cohort study
    Best, Catherine Susan
    Matheson, Catriona
    Robertson, James
    Ritchie, Trina
    Cowden, Fiona
    Dumbrell, Josh
    Duncan, Clare
    Kessavalou, Karthigayan
    Woolston, Caroline
    Schofield, Joe
    BMJ OPEN, 2024, 14 (03):
  • [40] Predictors of long-term retention on opioid agonist treatment with buprenorphine: a 6-year, community-based retrospective cohort study in India
    Rao, Ravindra
    Gupta, Swati
    Swaminathan, Prashanth
    Gupta, Vivek
    Dhawan, Anju
    Agrawal, Alok
    Ambekar, Atul
    JOURNAL OF SUBSTANCE USE, 2020, 25 (05) : 489 - 494